Advicenne News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.10.23	Advicenne announces the results of its capital increase with preferential subscription rights (Businesswire)
02.07.21	Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA (GlobeNewswire)
23.06.21	Advicenne Successfully Raises Circa € 9.4 Million in a Placement Reserved to a Category of Persons (Businesswire)
17.05.21	Advicenne reçoit un avis positif de la FDA sur la procédure d'approbation et l’Agence accepte le protocole modifié de l'étude de phase III pour son traitement de l'acidose tubulaire rénale distale (AT (GlobeNewswire)
21.03.19	Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019 (Businesswire)
12.03.19	Advicenne Announces Submission of European Marketing Authorization Application (MAA) for ADV7103 as Treatment for Distal Renal Tubular Acidosis (dRTA) (Businesswire)
07.01.19	Advicenne’s Flagship ADV7103 Receives Authorization for Pivotal Phase II/III Cystinuria Study in Belgium (Businesswire)
26.10.18	Advicenne Wins Prestigious Prix Galien - Medstartup Award for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcomes (Businesswire)
15.10.18	Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada (Businesswire)
04.10.18	Advicenne to Present Additional Data on ADV7103 at the European Society for Paediatric Nephrology During Its 51st Annual Meeting (Businesswire)
25.09.18	Advicenne Prepares its Expansion with Highly Experienced Industry Professionals (Businesswire)
20.09.18	Advicenne Reports First-Half 2018 Results and Confirms Outlook for 2018 (Businesswire)
12.09.18	Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation (Businesswire)
11.09.18	CORRECTING and REPLACING: Advicenne to Host a Conference Call on September 12, 2018 at 6 PM to Comment Its Recent Developments (Businesswire)
11.09.18	Advicenne to Host a Conference Call on September 12, 2018 at 6 PM to Comment on the Latest Positive Developments of Its Product Portfolio (Businesswire)
05.09.18	Advicenne Announces FDA Clearance of IND to Commence Pivotal Phase 3 Trial of ADV7103 for Distal Renal Tubular Acidosis (Businesswire)
03.07.18	Advicenne bestätigt Sicherheit und Wirksamkeit von ADV7103 nach 24-monatiger Phase-III-Erweiterungsstudie (Businesswire)
02.07.18	Advicenne Confirms ADV7103’ Safety and Efficacy after 24 Months in the Phase III Extension Study (Businesswire)
12.02.18	Advicenne Announces Its Financial Calendar for 2018 and Cash Position as of December 31st, 2017 (Businesswire)
24.01.18	Advicenne Appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs (Businesswire)
05.12.17	Advicenne raises €27 million in successful IPO on Euronext Paris (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu Advicenne SA

Aktien Top/Flop

Meistgelesene Nachrichten